KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Inventory (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 15 years of Change in Inventory data on record, last reported at $77.4 million in Q4 2025.

  • For Q4 2025, Change in Inventory fell 47.53% year-over-year to $77.4 million; the TTM value through Dec 2025 reached $524.2 million, up 1.33%, while the annual FY2025 figure was $524.2 million, 1.33% up from the prior year.
  • Change in Inventory reached $77.4 million in Q4 2025 per VRTX's latest filing, down from $131.1 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $182.5 million in Q3 2024 and bottomed at -$2.0 million in Q1 2022.
  • Average Change in Inventory over 5 years is $79.7 million, with a median of $77.9 million recorded in 2022.
  • Peak YoY movement for Change in Inventory: tumbled 108.77% in 2022, then surged 4230.0% in 2023.
  • A 5-year view of Change in Inventory shows it stood at $27.0 million in 2021, then soared by 190.0% to $78.3 million in 2022, then dropped by 10.6% to $70.0 million in 2023, then skyrocketed by 110.71% to $147.5 million in 2024, then tumbled by 47.53% to $77.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were $77.4 million in Q4 2025, $131.1 million in Q3 2025, and $148.6 million in Q2 2025.